The Vaccines Market Has Attracted The Attention Of Eleven Pharma Players, With Six Of These Accounting For Around 90% Of Vaccine Sales By Value.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c40622) has announced the addition of "New Drug Futures: Vaccines Chapter" to their offering.

Please note this chapter is taken from the "New Drug Futures" report. Please search our site for more details.

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the vaccines sector. The report includes unique sales forecasts by major product.

We estimate that vaccines generated sales of over US$10.6 billion in 2005, with over 50% derived from traditional, domestic paediatric vaccines and the development of novel vaccines that can command price premiums.

The market is beginning to turn around after a period of slow growth and it is forecast to be worth nearly US$20 billion by 2010. Growth will be driven principally by the adolescent and adult vaccine segment of the market as well as the development of therapeutic vaccines.

The market has attracted the attention of eleven pharma players, with six of these accounting for around 90% of vaccine sales by value.

ROTAVIRUS 

It is estimated that all children over five years old are infected with rotavirus, however the severity of infection may vary between individuals. Acute gastroenteritis is responsible for around 2 million hospitalisations worldwide and 223,000 hospitalisations in industrialised countries annually. Rotavirus is the leading cause of death in children younger than five years of age and accounts for 20% to 25% of all deaths in this age group.

ZOSTER VIRUS

It is estimated that over 90% of adults in the US acquired chicken pox virus as children and between 15-20% experience reactivation during their lifetime. An estimated 800,000 US citizens are diagnosed with herpes zoster virus which may result in severe post herpetic neuralgia in 50%+ of cases.

CERVICAL CANCER VACCINES

Cervical cancer is a major global health problem, with nearly 500,000 new cases occurring each year worldwide. It is the second most common cancer and the third leading cause of cancer deaths in women worldwide.

LUNG CANCER VACCINES

Lung cancer affects more than 1.2 million patients a year, with around 500,000 in the US, Europe and Japan. Non-small cell lung cancer is one of the leading causes of death, resulting in the worst survival rates for all cancers and killing more patients than breast, colon and prostate cancer together.

Answering key business questions

-Merck and GSK are fighting for the lion's share of the as yet unexploited multi billion US$ cervical cancer vaccine market. What differentiates the two products and how might this affect their sales?

-Dendreon has an open market with its prostate cancer vaccine Provenge. But does it have the sales experience and marketing muscle to achieve sales estimated at US$799 million in 2011?

-Will GSK/Avant Immunotherapuetics' monovalent vaccine derived from human rotavirus strain Rotarix 2-dose regimen see off competition from Merck's Rotateq in the US$2 billion rotavirus market?

-In a sector free of competition, Merck faces considerable marketing challenges for its Herpes Zoster vaccine Zostamax. What are they?

This chapter covers:

- Current Market Size

- Addressable Patient Population

- Current Treatments

- Sales Drivers

- Sales Breakers

- Future Treatments - Early Stage

- Market Dynamics - Winners and Losers

- Key launches to 2011

- Competitor Ratio Analysis - Products

- Competitor Ratio Analysis - Companies

For more information visit http://www.researchandmarkets.com/reports/c40622